Barry Reisberg

Q: What Schools Are Affiliated With Barry Reisberg

Barry Reisberg is affiliated with the following schools: McGill University, Cornell University, New York University

Barry Reisberg's AcademicInfluence.com Rankings

Barry Reisberg

Biology

#6699

World Rank

#9470

Historical Rank

Neuroscience

#812

World Rank

#846

Historical Rank

biology Degrees

Download Badge

Biology

Barry Reisberg's Degrees

PhD Neurology Cornell University

Why Is Barry Reisberg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Barry Reisberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Global Deterioration Scale for assessment of primary degenerative dementia. (1982) (4573)
Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease (2011) (1656)
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease (2014) (1634)
Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. (1987) (1228)
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (1073)
Functional assessment staging (FAST). (1988) (1011)
Memantine in moderate-to-severe Alzheimer's disease. (2003) (923)
Nonpharmacological Therapies in Alzheimer’s Disease: A Systematic Review of Efficacy (2010) (848)
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) (693)
Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET) (2001) (627)
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. (1997) (592)
Mild cognitive impairment in the elderly (1991) (532)
Vascular cognitive impairment (2002) (512)
Global Deterioration Scale (GDS). (1988) (493)
Outcome over seven years of healthy adults with and without subjective cognitive impairment (2010) (475)
Functional Assessment Staging (FAST) in Alzheimer's Disease: Reliability, Validity, and Ordinality (1992) (451)
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease (2009) (411)
Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease (1997) (386)
Implementation of subjective cognitive decline criteria in research studies (2017) (333)
Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis (2012) (308)
Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) (1997) (299)
Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. (2015) (296)
Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease (2008) (293)
Common variants at MS 4 A 4 / MS 4 A 6 E , CD 2 AP , CD 33 and EPHA 1 are associated with late-onset Alzheimer ’ s disease (2011) (274)
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment (2006) (260)
Neuropsychological Prediction of Decline to Dementia in Nondemented Elderly (1999) (250)
The pre–mild cognitive impairment, subjective cognitive impairment stage of Alzheimer’s disease (2008) (249)
Prediction of longitudinal cognitive decline in normal elderly with subjective complaints using electrophysiological imaging (2006) (242)
Patterns of Motor Impairment in Normal Aging, Mild Cognitive Decline, and Early Alzheimer' Disease (1997) (240)
Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) Rating Scale (1997) (239)
Dementia: a systematic approach to identifying reversible causes. (1986) (219)
Mild cognitive impairment (2005) (213)
MRI and CSF studies in the early diagnosis of Alzheimer's disease (2004) (212)
Computed Tomography and Positron Emission Transaxial Tomography Evaluations of Normal Aging and Alzheimer's Disease (1983) (207)
Quantitative EEG correlates of cognitive deterioration in the elderly (1994) (199)
Relationships between Regional Neuronal Loss and Neurofibrillary Changes in the Hippocampal Formation and Duration and Severity of Alzheimer Disease (1997) (198)
Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2019) (194)
Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia (2018) (188)
Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. (1992) (182)
An overview of current concepts of Alzheimer's disease. (1982) (182)
Brief Cognitive Rating Scale (BCRS). (1988) (182)
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. (2006) (180)
The GDS/FAST Staging System (1997) (179)
Evidence and mechanisms of retrogenesis in Alzheimer's and other dementias: Management and treatment import (2002) (176)
Positron Emission Tomography in the Study of Aging and Senile Dementia (1980) (175)
Positron emission tomographic studies of aging and Alzheimer disease. (1983) (175)
Subjective Memory Complaints: Presence, Severity and Future Outcome in Normal Older Subjects (2007) (170)
Equilibrium and Limb Coordination in Mild Cognitive Impairment and Mild Alzheimer's Disease (1999) (166)
Retrogenesis: clinical, physiologic, and pathologic mechanisms in brain aging, Alzheimer’s and other dementing processes (1999) (166)
Stage‐specific behavioral, cognitive, and in vivo changes in community residing subjects with age‐associated memory impairment and primary degenerative dementia of the Alzheimer type (1988) (166)
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease (2004) (158)
The Brief Cognitive Rating Scale (BCRS) : findings in primary degenerativ dementia (PDD) (1983) (157)
The Alzheimer's Disease Activities of Daily Living International Scale (ADL-IS) (2001) (153)
A Longitudinal Study of Cognitive Function in Elderly Persons with Subjective Memory Complaints (1993) (152)
Stage specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer's disease:A study of 120 patients using BEHAVE-AD (1989) (150)
Diffusion Tensor Imaging of Frontal White Matter Microstructure in Early Alzheimer’s Disease: A Preliminary Study (2005) (148)
Effects of naloxone in senile dementia: a double-blind trial. (1983) (140)
Functional Staging of Dementia of the Alzheimer Type (1984) (140)
Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. (2014) (140)
Validity and Reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change (2017) (139)
Neurofibrillary pathology — correlation with hippocampal formation atrophy in Alzheimer disease (1996) (137)
Computed tomography evaluations of brain-behavior relationships in senile d dementia of the Alzheimer's type (1980) (136)
Atrophy of hippocampal formation subdivisions correlates with stage and duration of Alzheimer disease. (1995) (126)
Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease (1998) (121)
Diagnosis and Treatment of Senile Dementia (1989) (119)
Cerebellar atrophy in Alzheimer's disease—clinicopathological correlations (1999) (119)
Management of behavior disturbance in Alzheimer disease: current knowledge and future directions. (1992) (119)
THE BEHAVIOR PATHOLOGY IN ALZHEIMER'S DISEASE RATING SCALE (BEHAVE‐AD): RELIABILITY AND ANALYSIS OF SYMPTOM CATEGORY SCORES (1996) (110)
Mild cognitive impairment (MCI): a historical perspective (2008) (110)
An ordinal functional assessment tool for Alzheimer's-type dementia. (1985) (106)
Alzheimer's disease: longitudinal CT studies of ventricular change. (1989) (104)
Global measures: utility in defining and measuring treatment response in dementia (2007) (99)
Positron Emission Tomography and Computed Tomography Assessments of the Aging Human Brain (1984) (99)
Dementia staging in chronic care populations. (1994) (94)
Side effects associated with lithium therapy. (1979) (94)
The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome (2008) (94)
The neurologic syndrome of severe Alzheimer's disease. Relationship to functional decline. (1993) (93)
Motor/Psychomotor Dysfunction in Normal Aging, Mild Cognitive Decline, and Early Alzheimer's Disease: Diagnostic and Differential Diagnostic Features (1997) (86)
Alzheimer's Disease: The Standard Reference (1983) (83)
Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration (2007) (83)
The Empirical Behavioral Pathology in Alzheimer's Disease (E-BEHAVE-AD) Rating Scale (1996) (77)
Clinical response to choline plus piracetam in senile dementia: relation to red-cell choline level. (1981) (77)
Mortality and Temporal Course of Probable Alzheimer's Disease: A 5-Year Prospective Study (1996) (77)
Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline. (2008) (76)
Longitudinal course of normal aging and progressive dementia of the Alzheimer's type: A prospective study of 106 subjects over a 3.6 year mean interval (1986) (75)
18F-2-deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia. (1982) (74)
Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome (2011) (73)
Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. (2010) (71)
Cognition-independent neurologic symptoms in normal aging and probable Alzheimer's disease. (1991) (70)
BEHAVE-AD: A Clinical Rating Scale for the Assessment of Pharmacologically Remediable Behavioral Symptomatology in Alzheimer’s Disease (1987) (69)
2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease (2014) (65)
Abnormal Temporal Lobe Response in Alzheimer's Disease during Cognitive Processing as Measured by 11C-2-Deoxy-D-Glucose and PET (1987) (64)
Patterns of motor impairement in normal aging, mild cognitive decline, and early Alzheimer's disease. (1997) (64)
Towards a Science of Alzheimer's Disease Management: A Model Based Upon Current Knowledge of Retrogenesis (1999) (64)
Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain (2004) (61)
Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. (1997) (61)
The stage specific temporal course of Alzheimer's disease: functional and behavioral concomitants based upon cross-sectional and longitudinal observation. (1989) (59)
An overview of pharmacologic treatment of cognitive decline in the aged. (1981) (59)
Nimodipine in the Treatment of Probable Alzheimer’s Disease (1996) (58)
Dexamethasone suppression in dementia, depression, and normal aging. (1986) (57)
Institutionalization of Alzheimer's disease patients: reducing precipitating factors through family counseling. (1987) (55)
Remediable behavioral symptomatology in Alzheimer's disease. (1986) (55)
Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer’s Disease Rating Scale: the BEHAVE-AD-FW: methodology and reliability (2001) (54)
Diagnostic Criteria in Dementia: A Comparison of Current Criteria, Research Challenges, and Implications for DSM-V (2006) (54)
Long-term choline treatment of memory-impaired elderly patients. (1979) (53)
Regional correlation of PET and CT in senile dementia of the Alzheimer type. (1983) (52)
Senile Dementia of the Alzheimer Type: Diagnostic and Differential Diagnostic Features with Special Reference to Functional Assessment Staging (1985) (52)
The wills of older people: risk factors for undue influence (2009) (52)
A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium (2008) (50)
Pharmacologic Treatment of Alzheimer's Disease: A Methodologic Critique Based Upon Current Knowledge of Symptomatology and Relevance for Drug Trials (1992) (50)
Clinical Evaluation of Global Change in Alzheimer's Disease: Identifying Consensus (1996) (47)
Measuring cognition in advanced Alzheimer's disease for clinical trials. (2002) (47)
Milacemide: A Placebo‐Controlled Study in Senile Dementia of the Alzheimer Type (1992) (46)
STAGES OF COGNITIVE DECLINE (1984) (45)
Abnormal Intracellular Accumulation and Extracellular Aβ Deposition in Idiopathic and Dup15q11.2-q13 Autism Spectrum Disorders (2012) (44)
Clinical Symptoms Accompanying Progressive Cognitive Decline and Alzheimer’s Disease (1985) (44)
Diagnosis and assessment of the older patient. (1982) (43)
Ecopsychosocial Interventions in Cognitive Decline and Dementia (2016) (43)
Temporal Order of Cognitive and Functional Loss in a Nursing Home Population (1995) (42)
Vascular fibrosis and calcification in the hippocampus in aging, Alzheimer disease, and Down syndrome (2002) (40)
Behavioral Disturbances of Dementia: An Overview of Phenomenology and Methodologic Concerns (1996) (40)
Positron emission tomography in dementia. (1983) (40)
Rarity of the Alzheimer disease-protective APP A673T variant in the United States. (2015) (39)
Cognitive Function in Normal Aging and Early Dementia (1985) (39)
ADCS Prevention Instrument Project: ADCS-Clinicians' Global Impression of Change Scales (ADCS-CGIC), Self-rated and Study Partner-rated Versions (2006) (39)
The BEHAVE-AD Assessment System: A Perspective, A Commentary on New Findings, and A Historical Review (2014) (37)
Duration of neurofibrillary changes in the hippocampal pyramidal neurons (1998) (37)
Assessment of presenting symptoms. (1986) (36)
Functional Ability Correlates with Cognitive Impairment in Parkinson’s Disease and Alzheimer’s Disease (2007) (36)
Meta-analysis of genetic association with diagnosed Alzheimer’s disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing (2018) (36)
Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease. (1988) (36)
Age‐associated memory impairment: The clinical syndrome (1986) (36)
Neuromotor Changes in Alzheimer's Disease: Implications for Patient Care (1997) (34)
Application of Piagetian measures of cognition in severe Alzheimer's disease. (1990) (34)
Symptomatic Changes in CNS Aging and Dementia of the Alzheimer Type: Cross-sectional, Temporal, and Remediable Concomitants (1989) (34)
CORRELATIONS BETWEEN COMPUTERISED TOMOGRAPHIC CHANGES AND BEHAVIOURAL DEFICITS IN SENILE DEMENTIA (1979) (33)
The Effects of Mood Changes and Antidepressants on the Cognitive Capacity of Elderly Depressed Patients (1989) (33)
Overview of Methodologic Issues for Pharmacologic Trials in Mild, Moderate, and Severe Alzheimer's Disease (1996) (32)
Staging methods for the assessment of dementia: Perspectives. (1996) (32)
Memantine in moderately severe to severe Alzheimer's disease (AD): Results of a placebo-controlled 6-month trial (2000) (31)
Periventricular lucencies in the CT scans of aged and demented patients (1986) (31)
Prediction of cognitive decline in normal older persons without subjective cognitive impairment: A seven year longitudinal study (2009) (31)
Report of an International Psychogeriatric Association Special Meeting Work Group; Under the Cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association (1997) (30)
A clinical rating scale for symptoms of psychosis in Alzheimer's disease. (1985) (29)
Informant-rated activities-of-daily-living (ADL) assessments: results of a study of 141 items in the U.S.A., Germany, Russia, and Greece from the International ADL Scale Development Project. (1997) (27)
Dementia of the Alzheimer Type Recapitulates Ontogeny Inversely on Specific Ordinal and Temporal Parameters (1992) (26)
Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (26)
Cognitive decline in advanced age: Future directions for the psychometric differentiation of normal and pathological age changes in cognitive function (1986) (25)
Senile Dementia: Outlook for the Future (1987) (25)
Vascular cognitive impairment. (2001) (24)
Sister chromatid exchanges and cell cycle kinetics in Alzheimer's disease. (1984) (24)
Diagnosis of Alzheimer's Disease: Report of an International Psychogeriatric Association Special Meeting Work Group Under the Cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association (1997) (24)
Progression of Alzheimer's disease: variability and consistency: ontogenic models, their applicability and relevance. (1998) (23)
Novel pharmacologic approaches to the treatment of senile dementia of the Alzheimer's type (SDAT). (1983) (23)
A curriculum for education in geriatric psychiatry. (1988) (22)
Characteristics and Performance of a Modified Version of the ADCS-CGIC CIBIC+ for Mild Cognitive Impairment Clinical Trials (2009) (22)
Brain Failure: An Introduction to Current Concepts of Senility (1981) (21)
Clinical profiles of tardive dyskinesia. (1981) (20)
The 1999 IPA/Bayer Research Awards (2000) (20)
Assessing cognitive impairment and evaluating treatment effects: Psychometric performance tests. (1986) (20)
Alzheimer's Disease Update (1985) (20)
Piracetam in the treatment of cognitive impairment in the elderly (1982) (20)
Longitudinal study of dementia patients and aged controls: An approach to methodologic issues. (1989) (19)
First results on the effects of MAO inhibition on cognitive functioning in elderly depressed patients. (1983) (17)
Neurologic Markers of the Progression of Alzheimer's Disease (1997) (17)
Translations of Measurements and Scales: Opportunities and Diversities (2000) (17)
Neuropeptide modulation of cognition and memory in humans. (1980) (17)
Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease? (2005) (17)
Alzheimer's Disease: Longitudinal CT (1989) (17)
ALZHEIMER'S DISEASE AND MEDICAL DISEASE CONDITIONS: A PROSPECTIVE COHORT STUDY (2005) (17)
Cognitive-motor intervention in Alzheimer's disease: long-term results from the Maria Wolff trial. (2015) (17)
Clinical Features of Severe Dementia: Staging (2006) (15)
NYU computerized test battery for assessing cognition in aging and dementia. (1988) (15)
The Early Detection of Brain Pathology in Alzheimer’s Disease (1992) (14)
An entorhinal cortex sulcal pattern is associated with Alzheimer's disease (2009) (13)
Relating Memory to Functional Performance in Normal Aging to Dementia Using Hierarchical Bayesian Cognitive Processing Models (2013) (13)
Shift from fibrillar to nonfibrillar Abeta deposits in the neocortex of subjects with Alzheimer disease. (2001) (13)
The relationship between psychiatric assessments and cognitive test measures in mild to moderately cognitively impaired elderly [proceedings]. (1981) (13)
Cognition Related Functional, Praxis and Feeding Changes in CNS Aging and Alzheimer's Disease and their Developmental Analogies (1990) (13)
Multiregional Age-Associated Reduction of Brain Neuronal Reserve Without Association With Neurofibrillary Degeneration or &bgr;-Amyloidosis (2017) (12)
Alzheimer's disease. Stages of cognitive decline. (1984) (12)
Correlation between functional assessment staging and the ‘Basic Age’ by the Binet scale supports the retrogenesis model of Alzheimer's disease: a preliminary study (2003) (11)
Dementia service centres in Austria: A comprehensive support and early detection model for persons with dementia and their caregivers – theoretical foundations and model description (2015) (11)
Extrapyramidal symptoms in patients with primary degenerative dementia. (1981) (11)
Clinical Diagnosis of Dementia: A Review (2002) (11)
Vascular Burden of the Brain (2003) (11)
Functional Assessment Staging of Dementia (2018) (11)
Catatonia associated with disulfiram therapy. (1978) (10)
Subjective memory complaints predict baseline but not future cognitive function over three years: results from the Western Australia Memory Study (2018) (10)
Do Many of the Behavioral and Psychological Symptoms of Dementia Constitute a Distinct Clinical Syndrome? Current Evidence Using the BEHAVE-AD (2000) (10)
Clinical features of a neuropathologically verified familial Alzheimer's cohort with onset in the fourth decade: comparison with senile onset Alzheimer's disease and etiopathogenic implications. (1989) (9)
Age-Associated Memory Impairment, Benign Forgetfulness and Dementia (1989) (9)
Clinical Assessment of Cognitive Decline in Normal Aging and Primary Degenerative Dementia: Concordant Ordinal Measures (1985) (9)
A Rational Psychological Approach to the Treatment of Behavioral Disturbances and Symptomatology in Alzheimer´s Disease Based upon Recognition of the Developmental Age (1998) (9)
Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial (2017) (9)
[Behavioral pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD): Spanish validation]. (2017) (9)
Reliability of the Modified Ordinal Scales of Psychological Development: A Cognitive Assessment Battery for Severe Dementia (1996) (9)
Immune dysfunctions: New targets of drug discovery for alzheimerapos;s disease and other cognitive disorders (1988) (8)
Commentary on “A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.” Subjective cognitive impairment as an antecedent of Alzheimer's dementia: Policy import (2009) (8)
Abnormal temporal lobe response in Alzheimerʼs disease during cognitive processing as measured by 11C-2-deoxy-D-glucose and PET (1987) (8)
Behavioral Symptoms in Dementia: Community-Based Research (1997) (7)
P.4.006 Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease (2003) (7)
Behavioral Intervention Approaches to the Treatment and Management of Alzheimer's Disease: A Research Agenda (1996) (7)
Guidelines for Drug Trials in the Treatment of Age-Associated Cognitive Decline and Alzheimer's Disease (1985) (7)
31. Staging Dementia (2010) (7)
775 Mathematical model of the rate of neurofibrillary changes in the hippocampal formation in end-stage Alzheimer disease (1996) (7)
Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons with Global Deterioration Scale Stage 2 (Subjective Cognitive Decline with Impairment). (2019) (6)
Clinicopathological Staging of Dynamics of Neurodegeneration and Neuronal Loss in Alzheimer Disease. (2020) (6)
Computed Tomography and Positron Emission Transaxial Tomography Evaluations of Normal Aging and (1983) (6)
Functional and Global Evaluations: Discussion (1997) (6)
Pharmacotherapy of senile dementia. (1980) (6)
Results of a placebo-controlled 6-month trial with memantine in moderate to severe Alzheimer's disease (AD) (2000) (6)
Staging: Relevance for Trial Design in Vascular Burden of the Brain (2003) (5)
652 The treatment of behavioral symptoms in dementia: Haloperidol, thioridazine, and fluoxetine: A double-blind, placebo-controlled, eight month study (1996) (5)
BPSD and the Psychosis of AD : Treatment Possibilities (2000) (5)
New and Promising Modalities for Assessment of Behavioral and Psychological Symptoms of Dementia (2000) (5)
Memantine and comprehensive, individualized, person-centered management (CI-PCM) of Alzheimer's disease: A randomized controlled trial (2013) (5)
Legal issues in Alzheimer's disease (1988) (4)
Psychopharmacologic Aspects of Cognitive Research in the Elderly: Some Current Perspectives (1979) (4)
Manifestations of Alzheimer’s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90 (2022) (4)
Neuropsychological and Neuropsychiatric Prediction of Global Cognitive Status Among Older Spanish-Speaking Hispanics and English-Speaking Whites (2014) (4)
Relationship between cognition and mood in geriatric depression. (1982) (4)
Fibrillar amyloid-β affects neurofibrillary changes but only in neurons already involved in neurofibrillary degeneration (2001) (4)
Comment on Dementia staging in chronic care populations (1994) (3)
Clinical Symptoms Accompany ing Progressive Cognitive Decline and Alzheimer's Disease Relationship to "Denial" and Ability to Give Informed Consent (1985) (3)
Psychometric Cognitive Decline Precedes the Advent of Subjective Cognitive Decline in the Evolution of Alzheimer’s Disease (2020) (3)
A 10-day training program for persons with dementia and their carers: A practical nonpharmacological treatment program (2009) (3)
Office Management and Treatment of Primary Degenerative Dementia (1982) (3)
2. Alzheimer disease: the clinical syndrome; diagnostic and etiologic importance (1990) (3)
Alzheimer's Disease—Clinical Course: Methodologic Implications for Pharmacologic Trials (1992) (3)
Neuropathological Assessments: Discussion (1997) (3)
Which comes first: Subjective cognitive impairment (SCI) or cognitive change? and is SCI a frequently occurring stage in the evolution of Alzheimer- associated cognitive change? (2010) (2)
Psychostimulants and neuropeptides in geropsychiatry [proceedings]. (1980) (2)
CT, PET AND NUR BRAIN IMAGING IN AGING AND ALZHEIMERʼS DISEASE (1984) (2)
Familial nature of Alzheimer's disease? (1984) (2)
Efficacy of galantamine in probable vascular dementia: an effective option for managing behavioural problems (2002) (2)
How good are single and multiple domains for characterizing MCI patients at risk for AD? (2005) (2)
Pharmacologic treatment of aggressive syndromes. (1978) (2)
16 Clinical course and the neglected half of Alzheimer's disease (AD) (1996) (2)
Commentary on “Diagnosis of Alzheimer’s disease: Two decades of progress.” Symptomatology and biomolecular basis of Alzheimer’s: A synthesis (2005) (2)
Introduction: The 1995 Research Awards in Psychogeriatrics (1996) (1)
PET‐DEOXYGLUCOSE, CT AND NEUROPATHOLOGY STUDIES OF AGE RELATED WHITE MATTER PATHOLOGY IN NORMALS AND ALZHEIMER DISEASE (1988) (1)
A FREQUENCY ADDENDUM TO THE BEHAVIORAL PATHOLOGY IN ALZHEIMER's DISEASE RATING SCALE (BEHAVE-AD) (1999) (1)
Functional improvement from treatment with the NMDA antagonist memantine Results of a 28-week, randomized, placebo-controlled study in advanced Alzheimers disease (2003) (1)
Is Aging a Disease? Subjective Cognitive Impairment and Physiologic Factors (2016) (1)
Global cognitive trajectory patterns in Alzheimer's disease. (2022) (1)
O2-02-04 Prediction of decline in normal elderly to MCI or dementia: A 9-year prospective longitudinal analysis using standardized low resolution electromagnetic tomographic analysis (SLORETA) (2007) (1)
The Fast: A Brief, Practical, Comprehensive, Valid Functional Assessment for Alzheimer's Disease Staging, Diagnosis and Differential Diagnosis in the Primary Care Setting (2011) (1)
Translation and psychometric evaluation of a Persian version of the functional assessment staging scale (I-FAST) in older patients with mild cognitive impairment and Alzheimer’s disease in Iran (2021) (1)
P.4.005 Functional improvement from treatment with the NMDA antagonist memantine: Results of a 28-week, randomized, placebo-controlled study in advanced Alzheimer's disease (2003) (1)
SUBJECTIVE COGNITIVE DECLINE AND PROGRESSION TO DEMENTIA DUE TO AD AND NON-AD IN MEMORY CLINIC AND COMMUNITY-BASED COHORTS (2016) (1)
O1-02-03 A 4-year, 3 timepoint MRI hippocampal study of MCI transition to AD (2004) (1)
P3-043: A seven-year prospective study of outcome in older persons with and without subjective cognitive impairment (2008) (1)
Clinical trials: Neuropeptides and nootropics (1981) (1)
A retrogenic model for detecting abuse of institutionalized people with Alzheimer’s disease (2013) (1)
GLOBAL DETERIORATION SCALE (GDS) STAGE 2: PERSONS WITH SUBJECTIVE COGNITIVE IMPAIRMENT (SCI) ONLY SHOW SIGNIFICANT DECLINES IN GDS STAGING SYSTEM MEASURES OVER A 2-YEAR INTERVAL (2016) (1)
Supplementary Material for: Nonpharmacological Therapies in Alzheimer’s Disease: A Systematic Review of Efficacy (2017) (1)
Use of psychotropics in the world. (1978) (1)
Brief Cognitive Rating Scale (BCRS) 1988 (2004) (1)
Open-label extension studies and misinformation. Author's reply (2006) (0)
Remission of pre-mild cognitive impairment (MCI), subjective cognitive impairment (SCI): A two-year prospective study of demographic and behavioral markers (2012) (0)
HEURISTIC MODELING OF THE MENTAL PROGRESS OF PERSONS WITH NORMAL BRAIN AGING, SUBJECTIVE COGNITIVE IMPAIRMENT, MILD COGNITIVE IMPAIRMENT, ALZHEIMER'S DISEASE AND RELATED DEMENTIA DISORDERS (2009) (0)
BEHAVIORAL SYMPTOMS ARE A HARBINGER OF FURTHER COGNITIVE DECLINE IN A 2-YEAR LONGITUDINAL STUDY OF PERSONS WITH SUBJECTIVE COGNITIVE DECLINE (SCD) (2019) (0)
S2-02-01 Predicting MCI and dementia in elderly subjects with subjective complaints (2004) (0)
Neuropsychological correlates of early Alzheimer's disease (2000) (0)
Effects of a rater training program on the clinician interview based impression of change (cibic-plus) (2000) (0)
Neuroimaging and Electrophysiology: Discussion (1997) (0)
P1-399 Responders to memantine treatment in moderate to severe Alzheimer's disease (2004) (0)
, Steven Spanish-Speaking Hispanics and English-Speaking Whites Neuropsychological and Neuropsychiatric Prediction of Global Cognitive Status Among Older (2014) (0)
Supplementary Material for: Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial (2017) (0)
FUNCTIONAL, GLOBAL, AND COGNITIVE DECLINE CORRELATES TO ACCUMULATION OF ALZHEIMERʼS PATHOLOGY.: 9. (2006) (0)
CLINICAL CHARACTERISTICS OF DEMENTIA OF THE ALZHEIMER TYPE (AD) (1988) (0)
NOVEL THERAPEUTIC STRATEGIES FOR ALZHEIMER'S DISEASE AND RELATED DISORDERS (1988) (0)
Pharmacotherapy of Alzheimer's disease: present opportunities and future possibilities (1990) (0)
P3-182 Intraneuronal amyloid beta immunoreactivity is not a predictor of fibrillar plaque formation or neurofibrillary degeneration (2004) (0)
O2-01-01 Biomarkers for Alzheimer's disease improve early diagnosis (2004) (0)
Effect of comprehensive, individualized, person‐centered management on antidepressant usage in advanced Alzheimer’s persons in a 28‐week, randomized, controlled trial (2020) (0)
COMPREHENSIVE, INDIVIDUALIZED, PERSON-CENTERED MANAGEMENT PROGRAM IN SUBJECTS TREATED WITH MEMANTINE ENHANCES FUNCTIONING BY 750%, IN COMPARISON WITH MEMANTINE TREATMENT ALONE, IN PERSONS WITH MODERATE-TO-SEVERE AD IN 28-WEEK RANDOMIZED CONTROLLED TRIALS (2017) (0)
Behavioral Pathology in Alzheimer's Disease Frequency-Weighted Severity Scale (2013) (0)
NEURONAL LOSS IN HIPPOCAMPAL FORMATION SUBDIVISIONS CORRELATES WITH DURATION AND STAGE OF ALZHEIMER DISEASE: 70 (1995) (0)
Relating memory to functional capacity from normal aging to dementia using hierarchical Bayesian cognitive processing models (2011) (0)
EFFECTS OF A COMPREHENSIVE, INDIVIDUALIZED, PERSON-CENTERED MANAGEMENT (CI-PCM) PROGRAM ON ANXIOLYTIC MEDICATION USAGE IN PERSONS WITH MODERATE-TO-SEVERE ALZHEIMER’S DISEASE (2018) (0)
Transcultural aspects of psychopharmacology. (1977) (0)
The 2003 IPA Research Awards in Psychogeriatrics (2004) (0)
BEHAVE-AD 1987 (2004) (0)
COMPREHENSIVE, INDIVIDUALIZED, PERSON-CENTERED MANAGEMENT PROGRAM REDUCES RISK OF HOSPITALIZATION BY 67% AND EMERGENCY ROOM VISITS BY 50% IN COMMUNITY-RESIDING, ADVANCED AD PERSONS IN A 28-WEEK RANDOMIZED, CONTROLLED TRIAL (2018) (0)
Cortical myelin profile variations in healthy aging brain: A T1w/T2w ratio study (2022) (0)
Contents Vol. 44, 2017 (2018) (0)
Global cognitive trajectory patterns in Alzheimer's disease - CORRIGENDUM. (2022) (0)
Retrogenesis in Alzheimer's disease: Functional and cognition relationships (2000) (0)
Introduction: The 1997 IPA/Bayer Research Awards (1997) (0)
Functional Assessment Staging (FAST) 1988 (2004) (0)
EVALUATION OF SYMPTOMS IN PERSONS WITH SUBJECTIVE COGNITIVE IMPAIRMENT (2014) (0)
The concept of retrogenesis in Alzheimer’s disease: ethical and forensic implications (2013) (0)
Global Deterioration Scale (GDS) 1982 (2004) (0)
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (0)
Open-Label Extension Studies and Misinformation—Reply (2006) (0)
ONE-YEAR GLOBAL OUTCOME OF A COMPREHENSIVE, INDIVIDUALIZED, PERSON CENTERED MANAGEMENT (CI-PCM) PROGRAM + MEMANTINE IN ADVANCED AD: A RANDOMIZED CONTROLLED TRIAL (2014) (0)
Emergency Issues in the Assessment and Management of Alzheimer's Disease (1986) (0)
POSITRON EMISSION TOMOGRAPHY (PET) AND COMPUTED TOMOGRAPHY (CT) EVALUATIONS COMBINED IN THE STUDY OF SENILE DEMENTIA OF THE ALZHEIMERʼS TYPE (1983) (0)
Neuropsychological test performance among Hispanic and white older adults (2020) (0)
CEREBELLAR ATROPHY AND B-AMYLOIDOSIS IN AD: 67 (1995) (0)
SINGLE CASE STUDY: CATATONIA ASSOCIATED WITH DISULFIRAM THERAPY (1978) (0)
The 1991 IPA Research Awards in Psychogeriatrics (1992) (0)
9 International working group on harmonization of dementia drug guidelines (1996) (0)
Impact of hormone replacement therapy (HRT) usage on 7-year outcome of older persons with subjective cognitive impairment (2011) (0)
Announcement (0)
Poster Session IITuesday, December 8, 2015 (2015) (0)
O1-05-01 Defining normality: Deviation from longitudinally derived cognitive norms more accurately predicts disease (2006) (0)
Clinical Rating Scale for Symptoms of Psychosis in Alzheimer's Disease (SPAD) 1985 (2004) (0)
Prognosis of Dementia (2002) (0)
Concluding Discussion (1997) (0)
Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) (0)
Antemortem functioning and pathologic relationships in the entorhinal cortex from mild cognitive impairment to most severe (fast stage 7f) alzheimer's disease: A comprehensive study (2009) (0)
PROGRESS OF NEUROFIBRILLARY PATHOLOGY IN THE CEREBRAL CORTEX IN SEVERE AD (1996) (0)
Convener's Foreword (1996) (0)
Depression and the apathy symptom are associated with poorer cognitive functioning in very old men (2020) (0)
Mock Trial of a Lawsuit Alleging Financial Fraud Against a 79 Year Old Woman by an Insurance Agent and an Insurance Company (2014) (0)
360 Contractures and loss of function in Alzheimer's disease (AD) (1996) (0)
Front & Back Matter (2012) (0)
P1-373 Etiopathogenic import of the utility of a neurodevelopmental functional measure in Alzheimer’s disease (AD) assessment (2006) (0)
Ab Deposition in Idiopathic and Dup15q11.2-q13 Autism Spectrum Disorders (2012) (0)
The 1993 Research Awards in Psychogeriatrics (1994) (0)
217 Urinary and fecal incontinence of Alzheimer's Disease (AD): Physical markers (1996) (0)
504 Medical conditions in Alzheimer's disease patients with 4/4 isotype of apolipoprotein E (1996) (0)
Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease (2018) (0)
O1-01-06 Age-associated neurofibrillary degeneration and neuronal loss in people free of beta-amyloidosis (2004) (0)
Electroencephalographic Evidence for Retrogenesis (2009) (0)
Prediction of the evalution of cognitive deterioration in the elderly using QEEG (1992) (0)
Relating memory to functional activities in normal aging, Alzheimer's disease and related disorders using hierarchical Bayesian cognitive processing models (2012) (0)
[Methodological problems in geriatric psychopharmacology]. (1983) (0)
The 2001 IPA Research Awards in Psychogeriatrics (2001) (0)
Appendix—International Psychogeriatric Association (IPA) (2002) (0)
Screening performance of the Healthy Brain Checklist in a community setting (2012) (0)
Course and treatment of Alzheimer's disease (1994) (0)
Effect of comprehensive, individualized, person‐centered management (CI‐PCM) on psychotropic medication usage in advanced Alzheimer’s persons in a 28‐week randomized controlled trial (2021) (0)
Functional Outcomes of a Comprehensive, Individualized, Person‐Centered Management Program in Advanced Alzheimer’s Disease(AD): Results from a 52‐Week Randomized Controlled Trial (2022) (0)
Effects of a comprehensive, individualized person-centered management program on persons with moderately severe Alzheimer's disease: A randomized controlled trial—comprehensive study findings (2015) (0)
P4-140 Neuropsychologic deficits in normal pressure hydrocephalus (2006) (0)
FAST, Symptomology and Differential Diagnostic Considerations 1986 (1988) (0)
MR-BASED HIPPOCAMPAL VOLUMETRIC MEASUREMENTS IN ALZHEIMER DISEASE – HISTOLOGICAL CORRELATIONS (1997) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Barry Reisberg?

Barry Reisberg is affiliated with the following schools: